82 related articles for article (PubMed ID: 21612575)
21. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments.
Brandes AA; Franceschi E; Tosoni A; Hegi ME; Stupp R
Clin Cancer Res; 2008 Feb; 14(4):957-60. PubMed ID: 18281526
[TBL] [Abstract][Full Text] [Related]
23. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
[TBL] [Abstract][Full Text] [Related]
24. Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinib.
Kim JC; Ali MA; Nandi A; Mukhopadhyay P; Choy H; Cao C; Saha D
Indian J Biochem Biophys; 2005 Dec; 42(6):358-65. PubMed ID: 16955736
[TBL] [Abstract][Full Text] [Related]
25. Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach.
Fan QW; Specht KM; Zhang C; Goldenberg DD; Shokat KM; Weiss WA
Cancer Res; 2003 Dec; 63(24):8930-8. PubMed ID: 14695210
[TBL] [Abstract][Full Text] [Related]
26. [HIT-GBM: multicenter study of treatment of children with malignant glioma].
Wolff JE; Boos J; Kühl J
Klin Padiatr; 1996; 208(4):193-6. PubMed ID: 8926684
[TBL] [Abstract][Full Text] [Related]
27. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
Mantha AJ; Hanson JE; Goss G; Lagarde AE; Lorimer IA; Dimitroulakos J
Clin Cancer Res; 2005 Mar; 11(6):2398-407. PubMed ID: 15788691
[TBL] [Abstract][Full Text] [Related]
28. New chemotherapy options for the treatment of malignant gliomas.
Soffietti R; Rudà R; Trevisan E
Anticancer Drugs; 2007 Jul; 18(6):621-32. PubMed ID: 17762390
[TBL] [Abstract][Full Text] [Related]
29. Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma.
Munson JM; Fried L; Rowson SA; Bonner MY; Karumbaiah L; Diaz B; Courtneidge SA; Knaus UG; Brat DJ; Arbiser JL; Bellamkonda RV
Sci Transl Med; 2012 Mar; 4(127):127ra36. PubMed ID: 22461640
[TBL] [Abstract][Full Text] [Related]
30. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
Bax DA; Gaspar N; Little SE; Marshall L; Perryman L; Regairaz M; Viana-Pereira M; Vuononvirta R; Sharp SY; Reis-Filho JS; Stávale JN; Al-Sarraj S; Reis RM; Vassal G; Pearson AD; Hargrave D; Ellison DW; Workman P; Jones C
Clin Cancer Res; 2009 Sep; 15(18):5753-61. PubMed ID: 19737945
[TBL] [Abstract][Full Text] [Related]
31. Erlotinib in glioblastoma: lost in translation?
Karpel-Massler G; Westhoff MA; Kast RE; Wirtz CR; Halatsch ME
Anticancer Agents Med Chem; 2011 Oct; 11(8):748-55. PubMed ID: 21707495
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy for low-grade gliomas: lessons and questions.
Raizer J
Oncology (Williston Park); 2014 Dec; 28(12):1043-4, 1051. PubMed ID: 25510804
[No Abstract] [Full Text] [Related]
33. Emerging targeted therapies for glioma.
Miller JJ; Wen PY
Expert Opin Emerg Drugs; 2016 Dec; 21(4):441-452. PubMed ID: 27809598
[TBL] [Abstract][Full Text] [Related]
34. Case-specific potentiation of glioblastoma drugs by pterostilbene.
Schmidt L; Baskaran S; Johansson P; Padhan N; Matuszewski D; Green LC; Elfineh L; Wee S; Häggblad M; Martens U; Westermark B; Forsberg-Nilsson K; Uhrbom L; Claesson-Welsh L; Andäng M; Sintorn IM; Lundgren B; Lönnstedt I; Krona C; Nelander S
Oncotarget; 2016 Nov; 7(45):73200-73215. PubMed ID: 27689322
[TBL] [Abstract][Full Text] [Related]
35. Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma.
Lobo MR; Kukino A; Tran H; Schabel MC; Springer CS; Gillespie GY; Grafe MR; Woltjer RL; Pike MM
PLoS One; 2015; 10(12):e0144488. PubMed ID: 26645398
[TBL] [Abstract][Full Text] [Related]
36. Metabolic models predict fotemustine and the combination of eflornithine/rifamycin and adapalene/cannabidiol for the treatment of gliomas.
Kishk A; Pires Pacheco M; Heurtaux T; Sauter T
Brief Bioinform; 2024 Mar; 25(3):. PubMed ID: 38701414
[TBL] [Abstract][Full Text] [Related]
37. RETRACTED: IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas.
Mihajluk K; Simms C; Reay M; Madureira PA; Howarth A; Murray P; Nasser S; Duckworth CA; Pritchard DM; Pilkington GJ; Hill R
Cancer Lett; 2019 Aug; 458():29-38. PubMed ID: 31129148
[TBL] [Abstract][Full Text] [Related]
38. Targeting glioma-initiating cells via the tyrosine metabolic pathway.
Yamashita D; Bernstock JD; Elsayed G; Sadahiro H; Mohyeldin A; Chagoya G; Ilyas A; Mooney J; Estevez-Ordonez D; Yamaguchi S; Flanary VL; Hackney JR; Bhat KP; Kornblum HI; Zamboni N; Kim SH; Chiocca EA; Nakano I
J Neurosurg; 2020 Feb; 134(3):721-732. PubMed ID: 32059178
[TBL] [Abstract][Full Text] [Related]
39. Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas.
Krishnan S; Rao RD; James CD; Sarkaria JN
Front Biosci; 2003 Jan; 8():e1-13. PubMed ID: 12456322
[TBL] [Abstract][Full Text] [Related]
40. Emerging patents in the therapeutic areas of glioma and glioblastoma.
Harris M; Svensson F; Kopanitsa L; Ladds G; Bailey D
Expert Opin Ther Pat; 2018 Jul; 28(7):573-590. PubMed ID: 29950117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
